KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe
KalVista Pharmaceuticals, Inc. (KALV)
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kalvista.com
Company Research
Source: Business Wire
Findings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient survey highlights barriers linked to injectable therapies FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), presented at the 20th German Allergy Congress in Düsseldorf, Germany from October 2–4, 2025. Across multiple ePoster presentations, EKTERLY demonstrated the ability to rapidly halt the progression of HAE attacks, deliver fast symptom relief and address key barriers associated with injectable therapies. Additional survey findings from German patients further highlight the urgent need for access to innovative on-demand HAE treatments across Europe.“The data presented at DGAKI underscore the transformative potential of EKTERLY for peop
Show less
Read more
Impact Snapshot
Event Time:
KALV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALV alerts
High impacting KalVista Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALV
News
- KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.MarketBeat
- KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects [Yahoo! Finance]Yahoo! Finance
- KalVista Pharmaceuticals Inc (KALV) Q3 2026 Earnings Call Highlights: Strong EKTERLY Launch and ... [Yahoo! Finance]Yahoo! Finance
- KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
KALV
Earnings
- 11/10/25 - Beat
KALV
Sec Filings
- 12/4/25 - Form 4
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- KALV's page on the SEC website